| Literature DB >> 33539753 |
Renée L Mulder1, Anna Font-Gonzalez2, Melissa M Hudson3, Hanneke M van Santen4, Erik A H Loeffen5, Karen C Burns6, Gwendolyn P Quinn7, Eline van Dulmen-den Broeder8, Julianne Byrne9, Riccardo Haupt10, W Hamish Wallace11, Marry M van den Heuvel-Eibrink12, Antoinette Anazodo13, Richard A Anderson14, Anke Barnbrock15, Joern D Beck16, Annelies M E Bos17, Isabelle Demeestere18, Christian Denzer19, Natascia Di Iorgi20, Holly R Hoefgen21, Rejin Kebudi22, Cornelis Lambalk23, Thorsten Langer24, Lillian R Meacham25, Kenny Rodriguez-Wallberg26, Catharyn Stern27, Eveline Stutz-Grunder28, Wendy van Dorp29, Margreet Veening8, Saskia Veldkamp30, Eline van der Meulen31, Louis S Constine32, Lisa B Kenney33, Marianne D van de Wetering34, Leontien C M Kremer2, Jennifer Levine35, Wim J E Tissing36.
Abstract
Female patients with childhood, adolescent, and young adult cancer are at increased risk for fertility impairment when treatment adversely affects the function of reproductive organs. Patients and their families desire biological children but substantial variations in clinical practice guidelines reduce consistent and timely implementation of effective interventions for fertility preservation across institutions. As part of the PanCareLIFE Consortium, and in collaboration with the International Late Effects of Childhood Cancer Guideline Harmonization Group, we reviewed the current literature and developed a clinical practice guideline for fertility preservation in female patients who were diagnosed with childhood, adolescent, and young adult cancer at age 25 years or younger, including guidance on risk assessment and available methods for fertility preservation. The Grading of Recommendations Assessment, Development and Evaluation methodology was used to grade the available evidence and to form the recommendations. This clinical practice guideline leverages existing evidence and international expertise to develop transparent recommendations that are easy to use to facilitate the care of female patients with childhood, adolescent, and young adult cancer who are at high risk for fertility impairment. A complete review of the existing evidence, including a quality assessment, transparent reporting of the guideline panel's decisions, and achievement of global interdisciplinary consensus, is an important result of this intensive collaboration.Entities:
Year: 2021 PMID: 33539753 DOI: 10.1016/S1470-2045(20)30594-5
Source DB: PubMed Journal: Lancet Oncol ISSN: 1470-2045 Impact factor: 41.316